Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension.

By Roberto de Franchis. Journal of Hepatology, 2005

2,160 citations recorded by the source corpus.

Portal hypertension is associated with the most severe complications of cirrhosis, including ascites, hepatic encephalopathy, and bleeding from gastro-esophageal varices. Despite the progress achieved over the last decades, the 6-week mortality associated with variceal bleeding is still in the order of 10–20%. Awareness of the difficulty inherent to the evaluation of diagnostic tools and the design and conduct of good clinical trials for the treatment of portalhypertensionhas led to theorganization, since1986,of a series of consensus meetings. The first one was organized by Andrew Burroughs in Groningen, The Netherlands [1]. After Groningen, other meetings followed, in Baveno in 1990 (Baveno I) [2] and in 1995 (Baveno II) [3,4], in Milan in 1992 [5], in Reston, USA, in 1996 [6], in Stresa in 2000 (Baveno III) [7,8], again in Baveno in 2005 (Baveno IV) [9,10], and in Atlanta in 2007 [11]. The aims of these meetings were to develop definitions of key events in portal hypertension and variceal bleeding, to review the existing evidence on the natural history, the diagnosis and the therapeutic modalities of portal hypertension, and to issue evidence-based recommendations for the conduct of clinical trials and the management of patients. All these meetings were successful and produced consensus statements on some important points, although some issues remained unsettled. To continue the work of the previous meetings, a Baveno V workshop was held on May 21–22, 2010. The workshop was attended by many of the experts responsible for most of the major achievements of the last years in this field. Many of them had attended the previous meetings as well. The main fields of discussion of the Baveno V workshop were the same as in Baveno I–IV, i.e. the definitions of key events concerning the bleeding episode and the therapeutic options in patients with portal hypertension. For each of these topics, a series of consensus statements were discussed and agreed upon. As in Baveno IV, whenever applicable, the level of existing evidence was evaluated and the recommendations were ranked according to the Oxford System [12] (i.e.: level of evidence from 1 = highest

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/32b7947b823d4ea998840e27a2bc270db247cd4a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (2015, background): “guidelines in place at specific times as proposed by liver societies.(18,19) The decision to perform upper-gastrointestinal endoscopy and liver imaging during the follow-up evaluation”
Transfusion strategies for acute upper gastrointestinal bleeding. (2013, neutral): “Child–Pugh class A or B 12/113 (11) 23/109 (21) 0.”
The clinical use of HVPG measurements in chronic liver disease (2009, positive): “On the basis of this evidence, current guidelines recommend the measurement of HVPG as soon as cirrhosis is diagnosed to help stratify patients' risk”
Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. (2014, background): “Antibiotic prophylaxis should ideally be given before or immediately after endoscopy [153].”
Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension (2015, background): “[6] in 1996, in Stresa, Italy, in 2000 (Baveno III) [7,8], again in Baveno in 2005 (Baveno IV) [9,10], in Atlanta in 2007 [11], and again in Stresa in 2010 (Baveno V) [12,13].”